108895-98-3

Basic information

• Product Name: Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester
• Synonyms: .1,3-Dihydro-5-phenyl-3-benzyloxycarbonylamino-2H-1,4-benzodiazepin-2-one;.3-benzyloxycarbonylamino-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one;.(RS)-3-<(benzyloxycarbonyl)amino>-2,3-dihydro-5-phenyl-1H-1,4-benzodiazepin-2-one;.1,3-dihydro-5-phenyl-3(R,S)-<(benzyloxycarbonyl)amino>-2H-1,4-benzodiazepin-2-one;3-[(benzyloxycarbonyl)amino]-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one;.1,3-dihydro-5-phenyl-3(R,S)-<(benzyloxycarbonyl)-amino>-2H-1,4-benzodiazepin-2-one
• CAS NO: 108895-98-3
• Molecular Formula: C23H19N3O3
• Molecular Weight: 385.422
• Mol File: 108895-98-3.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester(108895-98-3)
• EPA Substance Registry System: Carbamic acid, (2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-, phenylmethyl ester(108895-98-3)

Safety Data

• Hazardous Substances Data: 108895-98-3(Hazardous Substances Data)

Upstream product

• 161365-74-8 benzyl N-[[(2-benzoylphenyl)carbamoyl](1H-1,2,3-benzotriazol-1-yl)methyl]carbamate 
• 124676-19-3 2-(benzotriazol-1-yl)-N-(benzyloxycarbonyl)glycine 
• 2835-77-0 (2-aminophenyl)(phenyl)methanone 
• 174698-38-5 (+/-) 3-[N-carbobenzyloxy]amino-2,3-dihydro-1-[4-methoxybenzyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepine 
• 304-59-6 Rochelle's salt 
• 106849-44-9 2-α-(benzyloxycarbonyl)-glycinyl)-amino>-benzophenone 
• 103711-22-4 α-(Isopropylthio)-Nα-(benzyloxycarbonyl)glycine 
• 821800-04-8 [(2-benzoyl-phenylcarbamoyl)propylsulfanylmethyl]carbamic acid benzyl ester 
• 517874-18-9 (Benzotriazol-1-yl-chlorocarbonyl-methyl)-carbamic acid benzyl ester 
• 621-84-1 O-benzyl carbamate 
• 108895-97-2 2-α-(benzyloxycarbonyl)glycinyl)amino>benzophenone 

Downstream Products

• 153826-05-2 [1-(2-Hydroxy-ethyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 1060742-19-9 (1-Carbamoylmethyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-carbamic acid benzyl ester 
• 152665-66-2 [1-(3-Ethyl-2-oxo-pentyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 155412-55-8 [1-(3-Cyclohexyl-3-methyl-2-oxo-butyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 152665-63-9 [1-(3,3-Dimethyl-2-oxo-butyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]-carbamic acid benzyl ester 
• 161365-75-9 1,3-Dihydro-1-methyl-5-phenyl-3(S)-<<(R)-α-methylbenzyloxycarbonyl>amino>-2H-1,4-benzodiazepin-2-one 
• 161443-31-8 1,3-Dihydro-5-phenyl-3(S)-<<(R)-α-methylbenzyloxycarbonyl>amino>-2H-1,4-benzodiazepin-2-one 
• 103420-82-2 1H-Indole-2-carboxylic acid ((R)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-amide 
• 103420-77-5 devazepide 
• 155488-19-0 (R)-3-Amino-1-(2-cyclopentyl-2-oxo-ethyl)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 150007-40-2 3-Amino-1-(2-cyclopentyl-2-oxo-ethyl)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 155412-24-1 (R)-3-Amino-1-(3,3-dimethyl-2-oxo-butyl)-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 

Relevant articles and documents

COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS

The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

Discovery of clinical candidate BMS-906024: A potent pan-notch inhibitor for the treatment of leukemia and solid tumors

Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated doses in

1,4-Benzodiazepines as inhibitors of respiratory syncytial virus

Respiratory syncytial virus (RSV) is the cause of one-fifth of all lower respiratory tract infections worldwide and is increasingly being recognized as a serious threat to patient groups with poorly functioning immune systems. Our approach to finding a novel inhibitor of this virus was to screen a 20 000-member diverse library in a whole cell XTT assay. Parallel assays were carried out in the absence of virus in order to quantify any associated cell toxicity. This identified 100 compounds with IC50's less than 50 μM. A-33903 (18), a 1,4-benzodiazepine analogue, was chosen as the starting point for lead optimization. This molecule was moderately active and demonstrated good pharmacokinetic properties. The most potent compounds identified from this work were A-58568 (47), A-58569 (44), and A-62066 (46), where modifications to the aromatic substitution enhanced potency, and A-58175 (42), where the amide linker was modified.